HB4030, the Treatment Continuity Act of 2025, would amend Section 509 of the Public Health Service Act to expand an existing federal grant program focused on priority substance use disorder treatment needs to also cover serious mental illness. The bill directs the Secretary of Health and Human Services to use the program to support access to FDA-approved long-acting injectable medications for people with substance use disorders or serious mental illness, along with related lab testing, supportive counseling, and training for providers on using those medications in combination with clinical services.
The bill also revises the program’s reporting requirements by requiring HHS to submit an annual report to Congress beginning one year after enactment, describing program outcomes and whether treatment requirements were completed or substantially progressed based on clinician assessment. The amendments would apply only to grants awarded after enactment, so the bill would affect future funding under Section 509 rather than retroactively changing existing grants.
Impact
The bill would broaden the scope of Section 509 of the Public Health Service Act by adding serious mental illness alongside substance use disorder as a priority area for federal grant support. It would also narrow and specify the types of services eligible for funding, emphasizing long-acting injectable medications, associated counseling, lab testing, and provider training. In practice, the measure would affect HHS grant administration, treatment providers, and state or local entities that receive these grants for behavioral health services.
Sentiment
Based on the available context, the bill appears to have a generally supportive and bipartisan framing, as it was introduced by members from both parties and referred to committee without recorded opposition or votes. The title and structure suggest a policy approach aimed at improving treatment continuity and access to evidence-based care for behavioral health conditions. No committee transcript or vote history is available to indicate formal debate or division.
Contention
No specific points of contention are documented in the available materials because there are no committee transcripts or recorded votes. Potential areas of policy debate, however, could include the emphasis on long-acting injectable medications, the extent to which federal grants should prioritize medication-based treatment versus other services, and how clinician assessment should be used to measure progress or completion of treatment requirements. Any disagreement would likely center on treatment design, implementation, and federal grant priorities rather than the bill’s overall goal.